Effect of medical therapy for heart failure on segmental myocardial function in patients with ischemic cardiomyopathy

David S Blondheim1, Mark Kazatsker, Zvi Friedman

  • 1Unit of Noninvasive Cardiology, Department of Cardiology, Hillel-Yaffe Medical Center, Hadera, Rappaport Faculty of Medicine, Technion, Israel. blond@netvision.net.il

Insights

Heart failure medications improved regional heart muscle function and synchronization, but not global measures. Echocardiographic strain imaging revealed medication benefits on impaired segments, enhancing overall heart contraction homogeneity.

Area of Science:

  • Cardiology
  • Medical Imaging
  • Pharmacology

Background:

  • Current heart failure medication adjustment relies on global function, often overlooking regional myocardial performance.
  • Segmental function analysis is crucial for a comprehensive understanding of treatment efficacy.

Purpose of the Study:

  • To assess the feasibility of echocardiographic myocardial strain imaging in evaluating medication effects on global and segmental heart function in heart failure patients.
  • To compare global and regional strain, and time to peak strain before and after medication intake.

Main Methods:

  • Prospective study of 21 ambulatory heart failure patients.
  • Echocardiographic studies performed pre- and 2-hours post-medication.
  • Analysis of ejection fraction, global strain, regional strain, and time to regional peak strain.

Main Results:

  • No significant change in mean ejection fraction or global strain.
  • Medication improved peak strain in dysfunctional segments but decreased it in normal segments.
  • Improved segmental synchronization and reduced time intervals between systolic and postsystolic shortening.

Conclusions:

  • Echocardiographic myocardial strain imaging can detect medication-induced changes in segmental function and synchronization, which global measures miss.
  • Medications for heart failure tend to improve the homogeneity of left ventricular contraction.
  • Strain imaging offers a more sensitive assessment of heart failure pharmacotherapy than traditional global indices.

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.